Literature DB >> 31682654

Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

.   

Abstract

Year:  2011        PMID： 31682654      PMCID： PMC6802431          DOI： 10.14745/ccdr.v37i00a07

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN： 1188-4169


× No keyword cloud information.
  78 in total

1.  Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.

Authors:  K M Zangwill; J Droge; P Mendelman; S M Marcy; S Partridge; C Y Chiu; J Jing; S J Chang; I Cho; J I Ward
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

2.  Evaluation of a live, attenuated recombinant influenza vaccine in high school children.

Authors:  G M Schiff; C C Linnemann; L shea; B Lange; T Rotte
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

3.  Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.

Authors:  Janelle Rhorer; Christopher S Ambrose; Stephanie Dickinson; Holli Hamilton; Napoleon A Oleka; Frank J Malinoski; Janet Wittes
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

4.  A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.

Authors:  Robert F Breiman; W Abdullah Brooks; Doli Goswami; Rosanna Lagos; Charissa Borja-Tabora; Claudio F Lanata; Jaime A Cèspedes Londoño; Lucy Chai See Lum; Ruth Rappaport; Ahmad Razmpour; Robert E Walker; William C Gruber; Bruce D Forrest
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

5.  A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.

Authors:  Bruce D Forrest; A Duncan Steele; Louis Hiemstra; Ruth Rappaport; Christopher S Ambrose; William C Gruber
Journal:  Vaccine       Date:  2011-04-05       Impact factor: 3.641

6.  Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.

Authors:  J C King; J Treanor; P E Fast; M Wolff; L Yan; D Iacuzio; B Readmond; D O'Brien; K Mallon; W E Highsmith; J S Lambert; R B Belshe
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

7.  A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years.

Authors:  Patricia Tennis; Seth L Toback; Elizabeth Andrews; Lisa J McQuay; Christopher S Ambrose
Journal:  Vaccine       Date:  2011-05-17       Impact factor: 3.641

8.  Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly.

Authors:  J J Treanor; H R Mattison; G Dumyati; A Yinnon; S Erb; D O'Brien; R Dolin; R F Betts
Journal:  Ann Intern Med       Date:  1992-10-15       Impact factor: 25.391

9.  Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines.

Authors:  Suzanne E Ohmit; John C Victor; Esther R Teich; Rachel K Truscon; Judy R Rotthoff; Duane W Newton; Sarah A Campbell; Matthew L Boulton; Arnold S Monto
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

10.  Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.

Authors:  Manjusha J Gaglani; Pedro A Piedra; Gayla B Herschler; Melissa E Griffith; Claudia A Kozinetz; Mark W Riggs; Charles Fewlass; M Elizabeth Halloran; Ira M Longini; W Paul Glezen
Journal:  Arch Pediatr Adolesc Med       Date:  2004-01
View more
  3 in total

1.  Summary of the NACI systematic review and recommendation on the use of live attenuated influenza vaccine (LAIV) in HIV-infected individuals.

Authors:  Dorothy Moore; Ian Gemmill; Robyn Harrison
Journal:  Can Commun Dis Rep       Date:  2020-09-03

2.  Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada's experience with the live-attenuated influenza vaccine.

Authors:  Linlu Zhao; Kelsey Young; Althea House; Rob Stirling; Matthew Tunis
Journal:  Can Commun Dis Rep       Date:  2021-06-09

3.  Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis.

Authors:  Yu-Ju Lin; Chiao-Ni Wen; Ying-Ying Lin; Wen-Chi Hsieh; Chia-Chen Chang; Yi-Hsuan Chen; Chian-Hui Hsu; Yun-Jui Shih; Chang-Hsun Chen; Chi-Tai Fang
Journal:  Nat Commun       Date:  2020-01-16       Impact factor: 14.919
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.